Marijuana and the Cannabinoids

142 Martin
116. Justinova, Z., Tanda, G., Redhi, G. H., and Goldberg, S. R. (2003) Self-administration of
delta-9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology
(Berl) 169, 135–140.
117. Kaymakcalan, S., Ayhan, I. H., and Tulunay, F. C. (1977) Naloxone-induced or
postwithdrawal abstinence signs in delta-9-tetrahydrocannabinol-tolerant rats. Psychopharmacology
55, 243–249.
118. Hirschhorn, I. D. and Rosecrans, J. A. (1974) Morphine and delta-9-tetrahydrocannabinol:
Tolerance to the stimulus effects. Psychopharmacology 36, 243–253.
119. Lichtman, A. H., Sheikh, S. M., Loh, H. H., and Martin, B. R. (2001) Opioid and cannabinoid
modulation of precipitated withdrawal in ∆(9)-tetrahydrocannabinol and morphinedependent
mice. J. Pharmacol. Exp. Ther. 298, 1007–1014.
120. Bhargava, H. N. (1976) Effect of some cannabinoids on naloxone-precipitated abstinence
in morphine-dependent mice. Psychopharmacology 49, 267–270.
121. Bhargava, H. N. (1978) Time course of the effects of naturally occurring cannabinoids on
morphine abstinence syndrome. Pharmacol. Biochem. Behav. 8, 7–11.
122. Frederickson, R. C. A., Hewes, C. R., and Aiken, J. W. (1976) Correlation between the in
vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism
by l-(-)-∆ 9 -tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 199, 375–384.
123. Hine, B., Friedman, E., Torrelio, M., and Gershon, S. (1975) Morphine-dependent rats:
blockade of precipitated abstinence by tetrahydrocannabinol. Science 187, 443–445.
124. Vela, G., Ruiz-Gayo, M., and Fuentes, J.A. (1995) Anandamide decreases naloxone-precipitated
withdrawal signs in mice chronically treated with morphine. Neuropharmacology
34, 665–668.
125. Yamaguchi, T., Hagiwara, Y., Tanaka, H., et al. (2001) Endogenous cannabinoid, 2-
arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphinedependent
mice. Brain Res. 909, 121–126.
126. Ledent, C., Valverdej, O., Cossu, G., et al. (1999) Unresponsiveness to cannabinoids and
reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401–
404.
127. Mas-Nieto, M., Pommier, B., Tzavara, E. T., et al. (2001) Reduction of opioid dependence
by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy
of opioid addiction. Br. J. Pharmacol. 132, 1809–1816.
128. Rubino, T., Massi, P., Vigano, D., Fuzio, D., and Parolaro, D. (2000) Long-term treatment
with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal
syndrome. Life Sci. 66, 2213–2219.
129. Valverde, O., Maldonado, R., Valjent, E., Zimmer, A. M., and Zimmer, A. (2000) Cannabinoid
withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J.
Neurosci. 20, 9284–9289.
130. Navarro, M., Carrera, M. R. A., Fratta, W., et al. (2001) Functional interaction between
opioid and cannabinoid receptors in drug self-administration. J. Neurosci. 21, 5344–5350.
131. Fattore, L., Spano, M. S., Cossu, G., Deiana, S., and Fratta, W. (2003) Cannabinoid
mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats.
Eur. J. Neurosci. 17, 1723–1726.
132. De Vries, T. J., Homberg, J. R., Binnekade, R., Raaso, H., and Schoffelmeer, A. N. M.
(2003) Cannabinoid modulation of the reinforcing and motivational properties of heroin
and heroin-associated cues in rats. Psychopharmacology (Berl) 168, 164–169.
133. De Vries, T. J., Shaham, Y., Homberg, J. R., et al. (2001) A cannabinoid mechanism in
relapse to cocaine seeking. Nat. Med. 7, 1151–1154.
134. Vlachou, S., Nomikos, G. G., and Panagis, G. (2003) WIN 55,212-2 decreases the reinforcing
actions of cocaine through CB1 cannabinoid receptor stimulation. Behav. Brain
Res. 141, 215–222.